This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Increasing oncolytic viral therapy efficacy by agonizing tumor necrosis factor receptor superfamily member 9 (TNFRSF9; 4-1BB; CD137)	<p>Studies in mice suggest agonizing CD137 could improve the efficacy of oncolytic viral therapy. In a mouse model of breast cancer, an oncolytic vaccinia virus plus an anti-CD137 agonist antibody increased neutrophil and NK cell infiltration of tumors, decreased tumor growth and improved survival compared with either treatment alone. Next steps could include testing the approach with other viral therapies.</p> <p>SciBX 5(10); doi:10.1038/scibx.2012.268 Published online March 8, 2012</p>	Patent and licensing status unavailable	<p>John, L.B. <i>et al. Cancer Res.</i>; published online Feb. 7, 2012; doi:10.1158/0008-5472.CAN-11-2788</p> <p>Contact: Phillip K. Darcy, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia e-mail: phil.darcy@petermac.org</p>